AM105 / AbClon - LARVOL DELTA

AM105, first-in-class T cell engaging bispecific antibody for metastatic colon cancer, demonstrates strong anti-tumor activity by both neutralizing EGFR activity and engaging T cells (AACR 2025) - "Cetuximab, an approved anti-EGFR antibody, is effective in treating metastatic colorectal cancer with wild-type KRAS, improving survival. In vivo experiment using humanized 4-1BB mice have demonstrated excellent tumor cell elimination effects, and this therapeutic effect was still observed after newly introduction of tumor cells even in the absence of AM105 in the blood, suggesting the induction of T-cell memory function. Taken together, these results strongly suggested that AM105, a novel 4-1BB based bispecific antibody, exhibits potent anti-tumor T cell activity and could be promising therapeutic agent."

IO biomarker • Metastases • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • EGFR • KRAS • TNFRSF9

App Clone succeeds in paying 19 billion won worth of CB and third-party allocation paid-in capital increase [Google translation] (AbClon Press Release) - "Antibody drug development specialist AbClon announced on the 13th that it has completed the payment of a total of KRW 19 billion in CB and third- party allocation paid-in capital increase issuance proceeds...The company explained that with this funding, it will be able to focus on its ongoing clinical trials and R&D while improving its financial soundness. In particular, it will focus on completing Phase 2 clinical trials for the successful commercialization of its core pipeline , CAR-T treatment AT101. It also aims to successfully develop follow-up pipelines, such as switchable CAR-T treatment AT-501 and dual antibody treatment AM105, to meet market and investor expectations ."

Financing • Hematological Malignancies • Solid Tumor

AbClon, CB·CPS issuance of 31 billion decided.. Daily Partners Lead [Google translation] (Biospectator) - "AbClon held a board meeting on the 28th and announced that it decided to raise 31 billion won through a paid-in capital increase by issuing convertible bonds (CB) and third-party allocated convertible preferred shares (CPS)...AppClon explained that this funding acquisition will allow it to focus on clinical trials and R&D while improving its financial soundness. In particular, it emphasized that it will focus on completing Phase 2 clinical trials for the successful commercialization of its core AT101 and meeting market and investor expectations through the successful development of its core pipeline....AppClon plans to use this fund to focus on completing and commercializing phase 2 clinical trials of its CD19 CAR-T 'AT101' for blood cancer and developing the next-generation solid cancer HER2 switchable CAR-T 'AT501'. It also plans to strategically use it to develop T cell engager EGFRx4-1BB dual antibodies 'AM105 (colon cancer)' and 'AT109 (prostate cancer)'."

Financing • Colon Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Prostate Cancer • Solid Tumor

AM105: A novel bispecific antibody with Anti 4-1BB affibodies and EGFR antibody (AACR 2024) - "In cytotoxicity assays, AM105 exhibited superior tumor cell killing compared to cetuximab, particularly in EGFR-expressing cell lines. Our findings collectively establish AM105 as a potent therapeutic agent with strong anti-tumor T cell activity. The unique 4-1BB based Affibodies (AffiMab format) of AM105 holds promise for addressing the limitations of current bispecific antibodies, positioning it as a potential breakthrough in cancer immunotherapy."

IO biomarker • Hematological Malignancies • Oncology • Solid Tumor • BRAF

AbClone presents AT501∙ AM105 at the American Association for Cancer Research, “Presenting an innovative anticancer treatment approach” [Google translation] (AbClon Press Release) - "AbClon announced on the 11th that it participated in the American Association for Cancer Research (AACR) from the 5th to the 10th...and presented the latest research results on AT501 and AM105, new anticancer drug candidates...AbClone has designed the HER2 switch, which tracks only cancer proteins in solid tumors. It was confirmed in animal models that strong anticancer activity was maintained when administered together with switch CAR-T treatment. This is an innovative approach that is completely different from existing CAR-T treatments, and it is said that even in reactive or recurrent models, cancer can be completely suppressed by boosting the drug's efficacy again with just an additional switch....In addition, AM105 expanded the CD137 binding site to four and showed excellent efficacy in recruiting immune cells and activating T cells. It is expected to be easy to commercialize as it has characteristics that do not impede productivity and stability."

Preclinical • Oncology • Solid Tumor

AbClon discloses research results on anticancer new drug candidates AT501 and AM105 at the American Association for Cancer Research [Google translation] (AbClon Press Release) - "AbClon, a company specializing in CAR-T (chimeric antigen receptor -T) treatments , announced on the 4th that it will present research results on anticancer new drug candidates at the American Association for Cancer Research (AACR 2024) to be held in San Diego, USA in April...AbClon announces the research results of 'AT501', which introduces solid tumor CAR-T treatment technology based on a switchable platform, and 'AM105', which introduces AffiMab dual antibody technology. The presentation of AT501 will be presented by co-researcher Professor Jeong Jun-ho...AM105 effectively induced 4-1BB aggregation, and excellent efficacy was also confirmed in a stress model evaluation reflecting the low number of T cells in the solid tumor tumor microenvironment. At AACR 2024, we plan to announce the characteristics of AM105 and the results of research on its anticancer efficacy....'At AACR 2024, we plan to announce the research results of AT501 and AM105...'"

Preclinical • Oncology • Solid Tumor